Phase II study of single-agent bevacizumab in Japanese patients with recurrent malignant glioma

Japanese Journal of Clinical Oncology

Volumn 42, Issue 10, 2012, Pages 887-895

  Nagane, Motoo ^a   Nishikawa, Ryo ^b   Narita, Yoshitaka ^c   Kobayashi, Hiroyuki ^d   Takano, Shingo ^e   Shinoura, Nobusada ^f   Aoki, Tomokazu ^g   Sugiyama, Kazuhiko ^h   Kuratsu, Junichi ⁱ   Muragaki, Yoshihiro ^j   Sawamura, Yutaka ^k   Matsutani, Masao ^b  

^a KYORIN UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b SAITAMA MEDICAL UNIVERSITY   (Japan)

^c NATIONAL CANCER CENTER HOSPITAL   (Japan)

^d HOKKAIDO UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^e UNIVERSITY OF TSUKUBA   (Japan)

^f TOKYO METROPOLITAN KOMAGOME HOSPITAL   (Japan)

^g Kitano Hospital   (Japan)

^h HIROSHIMA UNIV SCHOOL OF MEDICINE   (Japan)

ⁱ KUMAMOTO UNIVERSITY   (Japan)

^j TOKYO WOMEN'S MEDICAL UNIVERSITY   (Japan)

^k Sawamura Neurosurgery Clinic   (Japan)

more..

Author keywords

Asian continental ancestry group; Bevacizumab; Glioblastoma; Glioma; Phase II

Indexed keywords

BEVACIZUMAB; CORTICOSTEROID; PROTEIN;

ADULT; AGED; APPENDICITIS; ARTICLE; BRAIN EDEMA; BRAIN HEMORRHAGE; CANCER CONTROL; CANCER GRADING; CANCER RECURRENCE; CANCER SURVIVAL; CLINICAL ARTICLE; CONGESTIVE HEART FAILURE; CONJUNCTIVAL HEMORRHAGE; CONVULSION; CORTICOSTEROID THERAPY; DELIRIUM; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; EPISTAXIS; FEMALE; FEVER; GINGIVA BLEEDING; GLIOBLASTOMA; HEMIPLEGIA; HUMAN; HYDROCEPHALUS; HYPERTENSION; INJECTION SITE BLEEDING; INTRACRANIAL PRESSURE; JAPANESE; LEUKOPENIA; MALE; MENSTRUAL IRREGULARITY; METRORRHAGIA; MONOTHERAPY; NEUTROPENIA; OPEN STUDY; OVERALL SURVIVAL; PHASE 2 CLINICAL TRIAL; PROGRESSION FREE SURVIVAL; PROTEINURIA; RECURRENT CANCER; SIDE EFFECT; SUBCUTANEOUS HEMORRHAGE; SURVIVAL RATE; TREATMENT RESPONSE; URINARY TRACT INFECTION; VENOUS THROMBOEMBOLISM;

ADULT; AGED; ANGIOGENESIS INHIBITORS; ANTIBODIES, MONOCLONAL, HUMANIZED; BRAIN NEOPLASMS; FEMALE; GLIOMA; HUMANS; MALE; MIDDLE AGED; NEOPLASM GRADING; NEOPLASM RECURRENCE, LOCAL; PROGNOSIS; SURVIVAL RATE; YOUNG ADULT;

EID: 84866759977     PISSN: 03682811     EISSN: 14653621     Source Type: Journal    
DOI: 10.1093/jjco/hys121     Document Type: Article

References (43)

1. Hou LC, Veeravagu A, Hsu AR, Tse VC. Recurrent glioblastoma multiforme: a review of natural history and management options. Neurosurg Focus 2006;20:E5.
2. Ohgaki H. Epidemiology of brain tumors. Methods Mol Biol 2009;472:323-42.
3. Stupp R, Hegi ME, Mason WP, et al. Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial. Lancet Oncol 2009;10: 459-66.
4. Stupp R, Mason WP, van den Bent MJ, et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 2005;352:987-96.
5. National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology. Central Nervous System Cancers V.2.2011.http://www.nccn.org/professionals/physician_gls/PDF/cns. pdf.
6. Lamborn KR, Yung WK, Chang SM, et al. Progression-free survival: an important end point in evaluating therapy for recurrent high-grade gliomas. Neuro Oncol 2008;10:162-70.
7. Ballman KV, Buckner JC, Brown PD, et al. The relationship between six-month progression-free survival and 12-month overall survival end points for phase II trials in patients with glioblastoma multiforme. Neuro Oncol 2007;9:29-38.
8. van den Bent MJ, Brandes AA, Rampling R, et al. Randomized phase II trial of erlotinib versus temozolomide or carmustine in recurrent glioblastoma: EORTC brain tumor group study 26034. J Clin Oncol 2009;27:1268-74.
9. Wong ET, Hess KR, Gleason MJ, et al. Outcomes and prognostic factors in recurrent glioma patients enrolled onto phase II clinical trials. J Clin Oncol 1999;17:2572-8.
10. Wick W, Puduvalli VK, Chamberlain MC, et al. Phase III study of enzastaurin compared with lomustine in the treatment of recurrent intracranial glioblastoma. J Clin Oncol 2010;28:1168-74.
11. Yung WK, Albright RE, Olson J, et al. A phase II study of temozolomide vs. procarbazine in patients with glioblastoma multiforme at first relapse. Br J Cancer 2000;83:588-93.
12. Huang H, Held-Feindt J, Buhl R, Mehdorn HM, Mentlein R. Expression of VEGF and its receptors in different brain tumors. Neurol Res 2005;27:371-7.
13. Chaudhry IH, O'Donovan DG, Brenchley PE, Reid H, Roberts IS. Vascular endothelial growth factor expression correlates with tumor grade and vascularity in gliomas. Histopathology 2001;39: 409-15.
14. Fukumura D, Xu L, Chen Y, Gohongi T, Seed B, Jain RK. Hypoxia and acidosis independently up-regulate vascular endothelial growth factor transcription in brain tumors in vivo. Cancer Res 2001;61: 6020-4.
15. Stefanik DF, Fellows WK, Rizkalla LR, et al. Monoclonal antibodies to vascular endothelial growth factor (VEGF) and the VEGF receptor, FLT-1, inhibit the growth of C6 glioma in a mouse xenograft. J Neurooncol 2001;55:91-100.
16. Hurwitz H, Fehrenbacher L, Novotny W, et al. Bevacizumab plus irinotecan, fluorouracil and leucovorin for metastatic colorectal cancer. N Engl J Med 2004;350:2335-42.
17. Johnson DH, Fehrenbacher L, Novotny W, et al. Randomised Phase II trial comparing bevacizumab plus carboplatin and paclitaxel with carboplatin and paclitaxel alone in previously untreated locally advanced or metastatic non-small-cell-lung cancer. J Clin Oncol 2004;22:2184-91.
18. Miller K, Wang M, Gralow J, et al. Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer. N Engl J Med 2007; 357:2666-76.
19. Yang JC, Haworth L, Sherry RM, et al. A randomised trial of bevacizumab, and anti-vascular endothelial growth factor antibody, for metastatic renal cancer. N Engl J Med 2003;349:427-34.
20. How Avastin is Designed to Work [Internet]. USA: Genentech, 2012 (cited 23 March 2012). http://www.avastin.com/avastin/patient/gbm/ index.html.
21. FDA Approves Drug for Treatment of Aggressive Brain Cancer [Internet]. MD, USA: Food and Drug Administration, 2009 (cited 12 January 2012). www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/2009/ucm 152295.htm.
22. Stark-Vance V. Bevacizumab and CPT-11 in the treatment of relapsed malignant glioma. Neuro-Oncol 2005;7:369. Abstract 342.
23. Vrendenburgh JJ, Desjardins A, Herndon JE, II, et al. Bevacizumab plus irinotecan in recurrent glioblastoma multiforme. J Clin Oncol 2007;25:4722-9.
24. Friedman HS, Prados MD, Wen PY, et al. Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma. J Clin Oncol 2009;27:4733-40.
25. Cloughesy T, Vredenburgh JJ, Day B, Das A, Friedman HS. Updated safety and survival of patients with relapsed glioblastoma treated with bevacizumab in the BRAIN study. J Clin Oncol 2010;28(Suppl):181s. Abstract 2008.
26. Kreisl TN, Kim L, Moore K, et al. Phase II trial of singleagent bevacizumab followed by bevacizumab plus irinotecan at tumor progression in recurrent glioblastoma. J Clin Oncol 2009; 27:740-5.
27. Raizer JJ, Grimm S, Chamberlain MC, et al. Phase 2 trial of single-agent bevacizumab given in an every-3-week schedule for patients with recurrent high-grade gliomas. Cancer 2010;116:5297-305.
28. Kairouz VF, Elias EF, Chahine GY, Comair YG, Dimassi H, Kamar FG. Final results of an extended phase II trial of bevacizumab and irinotecan in relapsed high grade gliomas. Neuro-Oncol 2010;12(Suppl 4):iv40-1. Abstract NO-20.
29. Gil MJ, de las Pen{ogonek}as R, Reynés G, et al. Bevacizumab plus irinotecan in recurrent malignant glioma showed high overall survival in a retrospective study. Neuro-Oncol 2010;12(Suppl. 4):iv53. Abstract NO-73.
30. Nghiemphu PL, Liu W, Lee Y, et al. Bevacizumab and chemotherapy for recurrent glioblastoma: a single-institution experience. Neurology 2009;72:1217-22.
31. Sathornsumetee S, Desjardins A, Vredenburgh JJ, et al. Phase II trial of bevacizumab and erlotinib in patients with recurrent malignant glioma. Neuro-Oncol 2010;12:1300-10.
32. Francesconi AB, Dupre S, Matos M, et al. Carboplatin and etoposide combined with bevacizumab for the treatment of recurrent glioblastoma multiforme. J Clin Neurosci 2010;17:970-4.
33. Soffietti R, Trevisan E, Ruda R, et al. Phase II trial of bevacizumab with fotemustine in recurrent glioblastoma: final results of a multicenter study of AINO (Italian Association of Neuro-oncology). J Clin Oncol 2011;29(Suppl):146. Abstract 2027.
34. Macdonald DR, Cascino TL, Schold SC, Cairncross JG. Response criteria for phase II studies of supratentorial malignant glioma. J Clin Oncol 1990;8:1277-80.
35. Trotti A, Colevas AD, Setser A, et al. CTCAE v3.0: development of a comprehensive grading system for the adverse effects of cancer treatment. Semin Radiat Oncol 2003;13:176-81.
36. Greenwood M. Reports on public health and medical subjects. The Error of Sampling of the Survivorship Tables. No 33, Appendix 1, London, UK: H.M Stationary Office, 1926.
37. Happold C, Roth P, Wick W, et al. ACNU-based chemotherapy for recurrent glioma in the temozolomide era. J Neurooncol 2009; 92:45-8.
38. Wen PY, Macdonald DR, Reardon DA, et al. Update response assessment criteria for high-grade gliomas: Response Assessment in Neuro-Oncology Working Group. J Clin Oncol 2010;28:1963-72.
39. Vredenburgh JJ, Cloughesy T, Samantc M, et al. Corticosteroid use in patients with glioblastoma at first or second relapse treated with bevacizumab in the BRAIN study. Oncologist 2010;15:1329-34.
40. Chamberlain MC, Johnston SK. Salvage therapy with single-agent bevacizumab for recurrent glioblastoma. J Neurooncol 2010;96:259-69.
41. A Study of Avastin (bevacizumab) in Combination with Temozolomide and Radiotherapy in Patients with Newly Diagnosed Glioblastoma [Internet]. USA: Clinicaltrials.gov, 2009 (cited 4 October 2011). http://clinicaltrials.gov/ct2/show/NCT00943826.
42. Temozolomide and Radiation Therapy with or Without Bevacizumab in Treating Patients with Newly Diagnosed Glioblastoma [Internet]. USA: Clinicaltrials.gov, 2009 (cited 4 October 2011). http://clinicaltrials.gov/ ct2/show/NCT00884741.
43. Van Meir EG, Hadjipanayis CG, Norden AD, et al. Exciting new advances in neuro-oncology: the avenue to a cure for malignant glioma. CA Cancer J Clin 2010;60:166-93.